Symbiotec Pharmalab IPO GMP today is Rs 185. Investors can use this GMP along with price band and subscription status for a better IPO review.
Listed
Mainboard IPO
SYMBIOTEC
Symbiotec Pharmalab IPO GMP, Subscription & Allotment Status Today
Symbiotec Pharmalab Limited is a pharmaceutical company engaged in developing and manufacturing active pharmaceutical ingredients (APIs), contract development and manufacturing (CDMO) solutions, and complex injectables. The company operates an integrated business model supported by research and development, fermentation, and organic chemistry capabilities. Its API portfolio primarily focuses on steroidal products, while its CDMO business offers development and manufacturing services for pharmaceutical, nutraceutical, and other life science companies. The company also develops complex injectable products, including double-chamber formats, and leverages its in-house API capabilities to support these offerings. Revenue is generated through the sale of APIs, CDMO services, and complex injectable products. Its business is supported by backward integration in key raw material processing, large-scale fermentation capacity, and multiple manufacturing facilities, enabling it to serve customers across regulated and global markets while expanding into new therapeutic and fermentation-based product categories.
- Price Band
- ₹938.00 - ₹988.00
- Lot Size
- 15 Shares
- Bidding Closes
- 27 Aug 2026
- Listing Date
- 01 Sept 2026
Current GMP Status
₹185
+18.72% vs upper band
Est. Listing Gain
+0.00%
Last Trend
01 Sept 2026
Listing Price
₹988.00
Retail Entry
₹14,820
IPO Details
Complete IPO information
| Current GMP | ₹185 |
|---|---|
| Estimated Listing Gain | +0.00% |
| Price Band | ₹938.00 - ₹988.00 |
| Issue Price | Approx ₹1757.00 Crores |
| Listing Price | ₹988.00 |
| Lot Size | 15 Shares |
| Issue Type | Mainboard |
| Registrar | TBA |
| Exchange | NSE, BSE |
| Retail Quota | TBA |
| Overall Subscription | 71.26x |
| Listing Date | 01 Sept 2026 |
| Minimum Investment | ₹14,820 |
Demand Tracker
Subscription Status
| Category | Shares Reserved | Shares Applied | Subscription (x) |
|---|---|---|---|
| QIB | 37.40 | 6433.59 | 172.03x |
| NII | 28.05 | 2065.35 | 73.63x |
| Retail | 65.45 | 848.10 | 12.96x |
| Overall Subscription | 131.25 | 9352.50 | 71.26x |
Head-to-head
Compare Symbiotec Pharmalab IPO with similar IPOs
Analysis
IPO Snapshot & Investor Takeaways
At the upper end of its price band, Symbiotec Pharmalab is priced at ₹988 per share. With a minimum lot size of 15 shares, a retail investor applying for one lot would need approximately ₹14,820 to participate in this Mainboard issue.
The latest recorded Grey Market Premium for Symbiotec Pharmalab stands at ₹185, implying an estimated listing gain of around 18.72% over the issue price if it holds until listing. This is down ₹75 from its previously recorded level. GMP reflects informal grey-market sentiment rather than a guaranteed outcome, and can change at any point until the day of listing.
As of the latest update, Symbiotec Pharmalab's IPO was subscribed 71.26x overall, with a category-wise breakdown of Retail 12.96x, QIB 172.03x, NII 73.63x.
Among the strengths highlighted in Symbiotec Pharmalab's IPO documents: Operates an integrated business across APIs, CDMO services and complex injectables.; Has one of India’s largest industrial-scale fermentation capacities with 700 KL capacity..
Investors should also weigh the risk factors Symbiotec Pharmalab has disclosed, including: Almost all revenue comes from API products, making the business dependent on API demand..
A share of Symbiotec Pharmalab's issue proceeds is earmarked for Repayment Of Borrowings: 112.5 (75%).
Mainboard IPOs list on the main platform of BSE/NSE, typically involve larger issue sizes, and draw participation across retail, HNI and institutional (QIB) investor categories.
Timeline
IPO roadmap at a glance
✓
Bidding Opens
24 Aug 2026
✓
Bidding Closes
27 Aug 2026
✓
Allotment
28 Aug 2026
✓
Listing
01 Sept 2026
Grey Market Premium
Daily GMP status
| Date | GMP | Change | Gain |
|---|---|---|---|
| 01 Sept 2026 | ₹185.00 | -₹75.00 | 18.72% |
| 31 Aug 2026 | ₹260.00 | -₹15.00 | 26.32% |
| 28 Aug 2026 | ₹275.00 | -₹10.00 | 27.83% |
| 27 Aug 2026 | ₹285.00 | -₹67.00 | 28.85% |
| 26 Aug 2026 | ₹352.00 | +₹12.00 | 35.63% |
| 25 Aug 2026 | ₹340.00 | -₹69.00 | 34.41% |
| 24 Aug 2026 | ₹409.00 | +₹64.00 | 41.40% |
| 22 Aug 2026 | ₹345.00 | +₹25.00 | 34.92% |
| 21 Aug 2026 | ₹320.00 | +₹120.00 | 32.39% |
| 20 Aug 2026 | ₹200.00 | - | 20.24% |
Swipe to see more →
Market Lot
Application size breakdown
| Category | Lots | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 1 Lot | 15 | ₹14,820 |
| Retail Maximum | 13 Lot | 195 | ₹1,92,660 |
| S-HNI Minimum | 14 Lot | 210 | ₹2,07,480 |
| S-HNI Maximum | 67 Lot | 1,005 | ₹9,92,940 |
| B-HNI Minimum | 68 Lot | 1,020 | ₹10,07,760 |
Swipe to see more →
Fund Utilization
Objects of the Issue & Official Documents
- Repayment Of Borrowings 112.5 (75%)
- General Corporate Purpose 37.5 (25%)
Issue Notes
Important takeaways before applying
Strengths
- Operates an integrated business across APIs, CDMO services and complex injectables.
- Has one of India’s largest industrial-scale fermentation capacities with 700 KL capacity.
- Backward integration reduces dependence on external sources for key intermediates.
- Develops differentiated double-chamber injectable products using in-house API capabilities.
- Long-term manufacturing agreements and strategic partnerships support future business growth.
Risks
- Almost all revenue comes from API products, making the business dependent on API demand.
- A large share of revenue comes from a few key customers, and losing them could hurt the business.
- The company depends on key suppliers for raw materials, and supply disruptions could affect operations.
- The company faces intense competition in both the API and CDMO businesses.
- Failure to meet repayment obligations or loan covenants could adversely affect the business and finances.
Analysis
Symbiotec Pharmalab IPO Details
The Symbiotec Pharmalab IPO is a mainboard book-built issue with a total issue size of approximately ₹1,757 crores. The public offer comprises a fresh issue of approximately ₹150 crores along with an Offer for Sale (OFS) of approximately 1,62,65,181 equity shares.
The IPO is scheduled to open for subscription on August 24, 2026 and close on August 27, 2026. The company has fixed the IPO price band at ₹938 to ₹988 per equity share, while the face value is ₹2 per equity share. The shares are proposed to be listed on both BSE and NSE.
Symbiotec Pharmalab Limited is a research and development-driven pharmaceutical and biotechnology company with capabilities across organic chemistry, biotechnology and complex injectables. Its business includes corticosteroid and steroidal-hormone active pharmaceutical ingredients (APIs).
| Particular | Details |
|---|---|
| IPO Open Date | August 24, 2026 |
| IPO Close Date | August 27, 2026 |
| Face Value | ₹2 Per Equity Share |
| IPO Price Band | ₹938 to ₹988 Per Share |
| Issue Size | Approx ₹1,757 Crores |
| Fresh Issue | Approx ₹150 Crores |
| Offer for Sale | Approx 1,62,65,181 Equity Shares |
| Issue Type | Book Built Issue |
| IPO Listing | BSE, NSE |
Note: Symbiotec Pharmalab IPO is scheduled from August 24 to August 27, 2026, with a price band of ₹938–₹988 per share and an issue size of approximately ₹1,757 crores. Investors should review the company's financial performance, valuation and offer documents before applying.
Analysis
Symbiotec Pharmalab IPO Reservation
The Symbiotec Pharmalab IPO reservation is divided among Qualified Institutional Buyers (QIBs), Non-Institutional Investors (NIIs), Retail Individual Investors and the anchor investor portion, where applicable.
As per the available category-wise allocation, 50% of the issue is allocated to Qualified Institutional Buyers excluding the anchor investor portion. 15% is allocated to Non-Institutional Investors, while 35% is reserved for Retail Individual Investors.
| Investor Category | Shares Offered | Shares (%) |
|---|---|---|
| Anchor Investor | – Shares | -% |
| QIB (Ex. Anchor) | – Shares | 50% |
| NII Shares Offered | – Shares | 15% |
| Retail Shares Offered | – Shares | 35% |
Note: The exact number of shares offered under each investor category is currently unavailable in the provided data. The table reflects the available percentage-wise reservation and can be updated once the final category-wise allocation is announced.
Analysis
Symbiotec Pharmalab IPO Anchor Investors
The Symbiotec Pharmalab IPO anchor bidding is scheduled for August 21, 2026, ahead of the public issue opening on August 24, 2026. The final anchor investor allocation, including the number of shares allotted and total anchor investment amount, is currently awaited.
The exact lock-in expiry dates for the anchor investor allocation will be updated once the final anchor allotment details and applicable IPO disclosures are available.
| Particular | Details |
|---|---|
| Anchor Bidding Date | August 21, 2026 |
| Anchor Investors List | |
| Shares Offered | – Shares |
| Anchor Size | – Cr. |
| Lock-in Period End Date – 50% Shares (30 Days) | 2026 |
| Lock-in Period End Date – Remaining 50% Shares (90 Days) | 2026 |
Note: The anchor investor names, number of shares offered, anchor issue size and exact lock-in expiry dates are currently unavailable in the provided data. These details should be updated after the final anchor allocation is announced.
Analysis
Symbiotec Pharmalab IPO Dates
The Symbiotec Pharmalab IPO will open for subscription on August 24, 2026 and close on August 27, 2026. Investors can submit their IPO applications during this subscription period.
The Symbiotec Pharmalab IPO allotment is expected to be finalized on August 28, 2026. Refunds for unsuccessful applicants and credit of shares to successful investors' demat accounts are scheduled for August 31, 2026. The company's equity shares are scheduled to list on BSE and NSE on September 1, 2026.
| IPO Event | Date |
|---|---|
| IPO Open Date | August 24, 2026 |
| IPO Close Date | August 27, 2026 |
| Basis of Allotment | August 28, 2026 |
| Refunds | August 31, 2026 |
| Credit to Demat Account | August 31, 2026 |
| IPO Listing Date | September 1, 2026 |
Note: The above table summarizes the Symbiotec Pharmalab IPO timeline, including the opening date, closing date, basis of allotment, refunds, demat credit and proposed BSE & NSE listing date.
Analysis
Symbiotec Pharmalab IPO Promoters and Holding Pattern
The promoters of Symbiotec Pharmalab are Anil Satwani, Kashish Satwani, Sushil Satwani and Satwani Holdings LLP. Before the IPO, the promoter and promoter group collectively hold 2,16,33,968 equity shares, representing approximately 34.47% of the company's pre-IPO shareholding.
Other shareholders hold 4,00,47,528 equity shares, accounting for approximately 65.53% of the pre-IPO equity share capital. The company's total pre-IPO outstanding equity shares stand at 6,16,81,496.
Based on the provided holding pattern, the total number of outstanding equity shares is expected to increase to 6,32,02,757 shares after completion of the IPO.
Promoters of Symbiotec Pharmalab
- Anil Satwani
- Kashish Satwani
- Sushil Satwani
- Satwani Holdings LLP
| Particular | Pre IPO Shares | Pre IPO % Shares | Post IPO Shares | Post IPO % Shares |
|---|---|---|---|---|
| Promoter and Promoter Group | 2,16,33,968 | 34.47% | – | -% |
| Others* | 4,00,47,528 | 65.53% | – | -% |
| Total | 6,16,81,496 | 100% | 6,32,02,757 | 100% |
Note: The post-IPO promoter and public shareholding percentages have not been provided. The table reflects the available pre-IPO shareholding and the provided total post-IPO equity share capital.
Analysis
Symbiotec Pharmalab IPO Objects of the Issue & Utilisation of Proceeds
Symbiotec Pharmalab proposes to utilise a major portion of the fresh issue proceeds towards reducing its outstanding debt. The company plans to use approximately ₹112.50 crores for the prepayment and/or repayment, either in full or in part, of certain outstanding borrowings.
The remaining net proceeds from the fresh issue are proposed to be utilised towards general corporate purposes, subject to applicable regulations and the final terms of the offer.
| Purpose | Amount |
|---|---|
| Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Company | ₹112.50 Cr. |
| General Corporate Purposes | ₹- |
Note: Of the approximately ₹150 crore fresh issue, ₹112.50 crores is proposed to be utilised towards repayment or prepayment of borrowings. The balance net proceeds may be used for general corporate purposes and applicable issue-related expenses.
Analysis
Symbiotec Pharmalab About Ipo
To be updated soon
Analysis
Symbiotec Pharmalab IPO Company Financial Report
Symbiotec Pharmalab reported steady growth in its business during the reported period. Revenue increased from ₹723.33 crores in FY2024 to ₹755.98 crores in FY2025 and further reached ₹872.26 crores in FY2026.
Profit After Tax (PAT) stood at ₹100.06 crores in FY2024 and declined slightly to ₹96.79 crores in FY2025. Profitability recovered in FY2026, with PAT increasing to ₹109.90 crores, the highest among the three reported financial years.
The company's total assets expanded consistently from ₹1,294.79 crores in FY2024 to ₹1,579.65 crores in FY2025 and ₹1,780.79 crores in FY2026, indicating continued expansion of its asset base.
| Period Ended | Revenue | Expense | PAT | Assets |
|---|---|---|---|---|
| 2024 | ₹723.33 Cr. | ₹590.99 Cr. | ₹100.06 Cr. | ₹1,294.79 Cr. |
| 2025 | ₹755.98 Cr. | ₹608.85 Cr. | ₹96.79 Cr. | ₹1,579.65 Cr. |
| 2026 | ₹872.26 Cr. | ₹709.90 Cr. | ₹109.90 Cr. | ₹1,780.79 Cr. |
Amount in ₹ Crores: From FY2024 to FY2026, Symbiotec Pharmalab's revenue increased by approximately 20.59%, while PAT increased by approximately 9.83%. FY2026 recorded the highest revenue, PAT and total assets among the three reported years.
Analysis
Symbiotec Pharmalab IPO Valuation – FY2026
The Symbiotec Pharmalab IPO valuation can be assessed using key financial indicators including Earnings Per Share (EPS), Return on Equity (ROE), Return on Capital Employed (ROCE), EBITDA Margin, PAT Margin, Return on Net Worth (RoNW) and Net Asset Value (NAV).
For FY2026, Symbiotec Pharmalab reported an ROE of 11.19% and ROCE of 11.56%. The company's EBITDA margin stood at 26.59%, while its PAT margin was 12.60%, reflecting its operating and net profitability for the financial year.
The company's basic Earnings Per Share (EPS) stood at ₹19.10, while Return on Net Worth (RoNW) was 9.48%. Net Asset Value (NAV) was reported at ₹184.69 per equity share. The debt-to-equity ratio has not been provided in the available data.
| KPI | Values |
|---|---|
| ROE | 11.19% |
| ROCE | 11.56% |
| EBITDA Margin | 26.59% |
| PAT Margin | 12.60% |
| Debt to Equity Ratio | – |
| Earning Per Share (EPS) | ₹19.10 (Basic) |
| Price / Earnings (P/E) Ratio | N/A |
| Return on Net Worth (RoNW) | 9.48% |
| Net Asset Value (NAV) | ₹184.69 |
Note: Based on the IPO price band of ₹938 to ₹988 and FY2026 EPS of ₹19.10, the implied P/E ratio works out to approximately 49.11x to 51.73x. At the upper price band of ₹988, the issue price is approximately 5.35 times the reported NAV of ₹184.69 per share.
Analysis
Symbiotec Pharmalab IPO Peer Group Comparison
The Symbiotec Pharmalab IPO peer group comparison includes listed pharmaceutical and life sciences companies such as Concord Biotech Limited, Divi’s Laboratories Limited, Cohance Lifesciences Limited and Laurus Labs Limited.
Investors can compare key parameters such as Earnings Per Share (EPS), P/E ratio, Return on Net Worth (RoNW), Net Asset Value (NAV) and income to understand Symbiotec Pharmalab's relative financial and valuation position. However, differences in scale, product mix and business models should also be considered.
| Company | EPS | PE Ratio | RoNW % | NAV | Income |
|---|---|---|---|---|---|
| Concord Biotech Limited | 24.78 | 61.07 | 14.00% | – | 1,054.90 Cr. |
| Divi’s Laboratories Limited | 96.75 | 87.80 | 16.50% | 631.00 | 10,560.00 Cr. |
| Cohance Lifesciences Limited | 4.69 | 95.02 | 7.00% | – | 2,268.55 Cr. |
| Laurus Labs Limited | 16.47 | 109.36 | 16.80% | – | 6,812.90 Cr. |
Note: Based on the provided FY2026 EPS of ₹19.10 and IPO price band of ₹938–₹988, Symbiotec Pharmalab's implied P/E is approximately 49.11x–51.73x. This is below the P/E ratios shown for the listed peers above, though direct valuation comparisons should account for differences in growth, profitability, scale and business mix.
Analysis
Symbiotec Pharmalab IPO Lead Managers aka Merchant Bankers
- JM Financial Ltd.
- Avendus Capital Pvt. Ltd.
- Motilal Oswal Investment Advisors Ltd.
- Nomura Financial Advisory & Securities (India) Pvt. Ltd.
FAQ
Symbiotec Pharmalab IPO FAQs
Symbiotec Pharmalab IPO price band is Rs 938.00 to Rs 988.00. Check the latest issue price, lot size and GMP together before applying.
Symbiotec Pharmalab IPO open date is 24 Aug 2026, close date is 27 Aug 2026, and listing date is 01 Sept 2026.
Symbiotec Pharmalab IPO lot size is 15 shares. The minimum retail investment is Rs 14,820.
Symbiotec Pharmalab is classified as a Mainboard IPO. This helps investors quickly understand the issue category and exchange segment.
Symbiotec Pharmalab IPO subscription status currently shows Retail 12.96x, QIB 172.03x, NII 73.63x, Overall 71.26x.
Symbiotec Pharmalab Limited is a pharmaceutical company engaged in developing and manufacturing active pharmaceutical ingredients (APIs), contract development and manufacturing (CDMO) solutions, and complex injectables. The company operates an integrated business model supported by research and development, fermentation, and organic chemistry capabilities. Its API portfolio primarily focuses on steroidal products, while its CDMO business offers development and manufacturing services for pharmaceutical, nutraceutical, and other life science companies. The company also develops complex injectable products, including double-chamber formats, and leverages its in-house API capabilities to support these offerings. Revenue is generated through the sale of APIs, CDMO services, and complex injectable products. Its business is supported by backward integration in key raw material processing, large-scale fermentation capacity, and multiple manufacturing facilities, enabling it to serve customers across regulated and global markets while expanding into new therapeutic and fermentation-based product categories.
Symbiotec Pharmalab IPO issue size is 2180 and the expected allotment date is 28 Aug 2026.
Community discussion
Comments
Share a useful question or insight about Symbiotec Pharmalab.
Leave a comment
Your email address will not be published. All comments and replies are reviewed before appearing.
Keep Exploring
Similar Recent IPOs
Mainboard
Reliance Jio
Price BandTBA
Current GMP₹185
Lot SizeTBA
Mainboard
HD Fire Protect
Price Band₹258.00 - ₹271.00
Current GMP₹55 · +20.3%
Lot Size55 Shares
Mainboard
Vishal Nirmiti
Price Band₹208.00 - ₹220.00
Current GMP₹-5 · +0.9%
Lot Size68 Shares
Mainboard
Nityas Gems and Jewellery
Price Band₹70.00 - ₹75.00
Current GMP₹7 · +1.3%
Lot Size200 Shares
Loading comments...